Viatris Inc. earnings overview

VTRS FY2026 Q1 · Calendar Q2 2026

Viatris Inc.

Viatris posted a Q1 beat with revenue of $3.52B and EPS of $0.59, driven by 18% YoY growth in Greater China and new product contributions. The pipeline advanced with EFFEXOR's Japan approval and progress toward FDA decisions on XULANE LO and fast-acting meloxicam. Management reaffirmed 2026 guidance and emphasized disciplined capital allocation with $2.5B in cash. The stock initially surged 9.3% before drifting back roughly 8.7%, suggesting investors are weighing whether China momentum and pipeline execution are sustainable against policy and supply risks.